Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Idogen

Mindre end 1K følgere

Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection.

Læs mere
Alle
Analyse
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse6.6.2023, 11.04

Idogen's Board of Directors proposes that liquidation is not to be resolved at the Annual General Meeting on June 8.

Idogen
Selskabsmeddelelse30.5.2023, 06.03

Idogen working for a sale of its proprietary technology platform

Idogen
Pressemeddelelse10.5.2023, 06.36

Redeye: Idogen - Q1 2023 – In a tough situation

Idogen

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Selskabsmeddelelse28.4.2023, 06.02

Idogen in discussions about a reversed merger. The company intends to add an agenda item at the annual general meeting on June 8 for possible liquidation

Idogen
Selskabsmeddelelse18.4.2023, 06.01

Idogen is investigating reverse acquisitions to avoid risk of liquidation

Idogen
Pressemeddelelse27.2.2023, 07.48

Redeye: Idogen Q4 2022 - The future is contingent on funding

Idogen
Selskabsmeddelelse24.2.2023, 11.04

Idogen publishes interim report for 1 January - 31 December 2022

Idogen
Pressemeddelelse7.2.2023, 07.22

BioStock: Idogen one of ten companies selected for field-leading event

Idogen
Pressemeddelelse31.1.2023, 12.17

Idogen invited by GJCF to participate in their 3[rd] Summit for NMOSD Tolerization

Idogen
Selskabsmeddelelse17.1.2023, 16.31

Idogen announces outcome of rights issue

Idogen
Pressemeddelelse9.1.2023, 07.03

Last day for subscription of shares in Idogen's rights issue is Friday January 13, 2023

Idogen
Pressemeddelelse12.12.2022, 07.14

Idogen's first clinical trial, "Toler8", briefly described in Blood

Idogen
Pressemeddelelse25.11.2022, 07.29

BioStock: Idogen strengthens the Board with Jan Holgersson

Idogen
Pressemeddelelse14.11.2022, 14.16

Idogen's financial contribution from Horizon 2020 now finalizes with a publication

Idogen
Selskabsmeddelelse8.11.2022, 17.01

Idogen carries out a rights issue of approximately SEK 43.7 million

Idogen
Selskabsmeddelelse1.11.2022, 18.16

Agneta Edberg elected as new Chairman of Idogen due to changes to the Board of Directors

Idogen
Pressemeddelelse17.10.2022, 06.03

Idogen: EU to disburse the remaining MSEK 4.7 of the Horizon grant

Idogen
Selskabsmeddelelse3.10.2022, 20.07

Idogen sharpens focus on its IDO 8 program and lowers operating expenditure

Idogen
Selskabsmeddelelse3.10.2022, 16.01

Idogen announces outcome of exercise period for warrants of series TO 5

Idogen
Pressemeddelelse27.9.2022, 07.51

BioStock: Exciting times for Idogen's new Chairman of the Board

Idogen
Forum opdateringer
Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or...
17.10.2022, 08.11
by Olivier A. de Goeij
0
Besøg forummet
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.